Avalo Therapeutics, Inc. - Common Stock (NQ:AVTX)
5.700
-0.890
(-13.51%)
Streaming Delayed Price
Updated: 12:18 PM EDT, Apr 4, 2025
Add to My Watchlist
All News about Avalo Therapeutics, Inc. - Common Stock


Nasdaq Rises 50 Points; US Manufacturing PMI Improves In September
September 22, 2023
Via Benzinga
Topics
Stocks
Exposures
US Equities

12 Health Care Stocks Moving In Friday's Pre-Market Session
September 22, 2023
Via Benzinga




12 Health Care Stocks Moving In Friday's Intraday Session
September 15, 2023
Via Benzinga


Dow Dips 100 Points; US Export Prices Rise 1.3% In August
September 15, 2023
Via Benzinga
Topics
Stocks
Exposures
US Equities

12 Health Care Stocks Moving In Friday's Pre-Market Session
September 15, 2023
Via Benzinga



12 Health Care Stocks Moving In Thursday's After-Market Session
September 14, 2023
Via Benzinga


12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 14, 2023
Via Benzinga


12 Health Care Stocks Moving In Wednesday's After-Market Session
September 13, 2023
Via Benzinga


12 Health Care Stocks Moving In Wednesday's Intraday Session
September 13, 2023
Via Benzinga


Nasdaq Gains 50 Points; US Inflation Rate Rises In August
September 13, 2023
Via Benzinga



12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 13, 2023
Via Benzinga



Why Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
September 13, 2023
Via Benzinga


Crude Oil Rises 2%; Avalo Therapeutics Shares Spike Higher
September 12, 2023
Via Benzinga
Topics
Stocks
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free